arrow
T

Tore K Kvien

Diakonhjemmet Hospital
H指数:109
被引数:5.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis

通过钙卫蛋白测量的系统性炎症与类风湿关节炎中自身抗体负荷的关联

2026-10-030
OAAI
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK-pot Collaboration

利用机器学习预测类风湿关节炎6至24个月内的缓解:JAK-pot Collaboration的见解

2026-04-060
OAAI
Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug-Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population

与类风湿关节炎和普通人群相比,接受疾病修饰抗风湿药物治疗的幼年特发性关节炎成年患者的健康相关生活质量

2026-01-010
PRE
Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis

定义巴思强直性脊柱炎疾病活动指数(BASDAI)截断值,以评估欧洲多国轴性脊柱关节炎患者队列中的疾病活动状态。

2025-12-020
OAAI
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

欧洲各国在组织治疗银屑病关节炎和轴向脊柱关节炎患者方面的国家医疗体系存在差异。

2025-06-010
OAAI
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

与生物制剂改善病情的抗风湿药物相比,接受JAK抑制剂治疗的风湿性关节炎患者发生主要不良心血管事件的发生率:来自国际注册研究合作的数据

2025-05-210
OAAI
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

识别甘氨酸与瓜氨酸基序对决定抗瓜氨酸蛋白抗体与HLA II类分子结合的影响:来自对6,900名斯堪的纳维亚类风湿关节炎患者自身抗体谱分析的研究启示

2025-04-300
OAAI
Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study

用于预测早期RA未缓解的机器学习模型的开发突出了RAID评分的强大预测重要性-来自北极研究的证据

2025-02-120
OAAI
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
2025-01-010
PRE
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
2024-10-011
OAAI
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic

类风湿关节炎或银屑病关节炎患者的间质性肺病起始生物制剂和对照: 来自5个北欧的数据

2024-09-011
OA
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
2024-08-190
OAAI
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
2024-07-011
OAAI
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial
2024-05-011
PRE
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
2024-04-151
OA
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
2024-04-016
PRE